Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension
- 1 April 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 75 (4) , 299-304
Abstract
Parenteral prostacyclin therapies remain first-line therapy for patients with pulmonary arterial hypertension (PAH) with class IV symptoms. In selected patients who have been clinically stabilized, switching to selexipag, a chemically distinct prostacyclin receptor agonist, may alleviate risks associated with long-term parenteral therapy. We report our experience with transition of patients from parenteral prostacyclin therapy to selexipag. From January 2016 to July 2017, patients with PAH at the Duke University Pulmonary Vascular Disease Center with functional class II symptoms on stable parenteral prostacyclin therapy were offered the opportunity to transition to selexipag. A standardized protocol was developed to guide titration of therapies. Patients underwent pre- and post-transition assessments of hemodynamics, echocardiography, laboratory biomarkers, and functional status. We studied 14 patients with PAH (11 women; median age 53 years) in total. Overall, 13 patients tolerated the switch to selexipag and remained on the drug at study completion, and 1 patient passed away due to progressive liver failure. Surrogate markers including NT-proBNP, 6MWD, RV function, and TAPSE, and right heart catheterization hemodynamics were similar before and after transition. The transition from parenteral prostanoid therapy to oral selexipag was overall well-tolerated in patients with stable PAH and functional class II symptoms. Finally, doses of selexipag up to 3200 μg twice daily were well-tolerated in patients who had been treated with prior parenteral prostacyclins.Keywords
This publication has 19 references indexed in Scilit:
- Transition from parenteral to oral treprostinil in pulmonary arterial hypertensionThe Journal of Heart and Lung Transplantation, 2017
- Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonarRevista Espanola de Cardiologia, 2016
- Selexipag for the Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2015
- Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertensionEuropean Respiratory Review, 2015
- Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjectsBritish Journal of Clinical Pharmacology, 2015
- Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist SelexipagAmerican Journal of Cardiovascular Drugs, 2015
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertensionRespiratory Medicine, 2008
- 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist ProdrugThe Journal of Pharmacology and Experimental Therapeutics, 2007
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996